A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma

What is the purpose of this trial?

The main purpose of this study is to compare how long patients with glioblastoma (GBM, a malignant brain cancer) live after receiving nivolumab every two weeks in addition to radiation therapy (RT), and then every four weeks, compared with patients receiving standard therapy with temozolomide in addition to RT.

Bristol-Myers Squibb Research and Development

Start Date: 09/12/2016

End Date: 03/01/2019

Last Updated: 02/22/2018

Study HIC#: 1604017516

Get Involved

For more information about this study, contact:
Insil Kim
+1 203-785-6747

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Joachim M Baehring

Principal Investigator